Dr Lalchandani Labs Limited is a **NABL-accredited** diagnostic healthcare provider with over **32 years** of institutional experience. Headquartered in **New Delhi**, the company provides an integrated suite of pathology, radiology, and laboratory management services. After transitioning from a partnership to a corporate entity in **2017**, the company is currently navigating a critical phase of financial restructuring and operational revival to stabilize its position in the competitive Delhi/NCR healthcare market. --- ### **Core Service Portfolio & Multi-Channel Delivery** The company operates an integrated diagnostic model catering to individual patients (**B2C**), healthcare institutions, and government bodies. * **Pathology & Specialized Testing:** Comprehensive services including **Biochemistry, Hematology, Histopathology, Microbiology, Molecular Pathology, DNA & Genetic Testing**, and **Immuno-Histochemistry**. * **Radiology & Imaging:** Diagnostic capabilities featuring **Digital X-ray, Ultrasound, Colour Doppler, 2D Echo, TMT, and ECG**. * **Hospital Lab Management (HLM):** End-to-end outsourcing solutions for small and medium-sized hospitals. Services are provided on a **management-fee or revenue-sharing basis**, encompassing equipment installation, staffing, and NABL accreditation support. * **Corporate & Government Health:** Empaneled with major institutions including **CGHS, DJB, MCD, and DDA** for preventive wellness packages and institutional health check-ups. * **Ancillary Services:** * **Home Collection:** Wide-reaching sample collection across Delhi/NCR with **same-day reporting** for eligible tests. * **Blood Bank Support:** Facilitated through sister concern **CPC Blood Bank**, providing whole human blood and apheresis services. --- ### **Operational Infrastructure & Technical Benchmarks** The company’s technical backbone is designed for high-volume processing and quality compliance. | Feature | Details | | :--- | :--- | | **Network Footprint** | **5 Self-sufficient Labs** and **15 Collection Centers** | | **Flagship Hub** | **Greater Kailash-1, New Delhi** (One-stop diagnostic center) | | **Processing Capacity** | Scalable to **1,000 samples per hour** | | **Quality Standards** | **NABL Accredited**; participant in **EQAS** with AIIMS and Vellore | | **Key Equipment Suppliers** | **Roche, Johnson & Johnson, Nicholas Piramal** | | **Human Capital** | Pathologists and technicians with **5–25 years** of experience | --- ### **Strategic Revival & Capital Restructuring** The company is currently executing a **Rights Issue** to address historical debt and regularize its financial standing. This move is central to its transition from a period of financial stress to a growth-oriented model. #### **The 2026 Rights Issue Framework** * **Issue Size:** Up to **4,33,20,000** Equity Shares aggregating **₹4.33 crore**. * **Pricing & Ratio:** Offered at **₹10 per share** (at par) with a **1:1 ratio** (one share for every one share held as of the **January 27, 2026** record date). * **Capital Expansion:** Authorized Capital was increased from **₹4.50 crore** to **₹11.00 crore** in late 2025 to facilitate this issuance. * **Utilization of Proceeds (Net: ₹4.11 crore):** * **Working Capital (₹1.27 crore):** To support day-to-day operations for **FY 2025-26**. * **Debt Regularization:** Repayment/settlement of outstanding borrowings and NPA accounts. * **Promoter Loan Adjustment:** Conversion of unsecured loans into equity to deleverage the balance sheet. * **General Corporate Purposes (Up to ₹1.08 crore):** Capped at **25%** for CAPEX and interest payments. --- ### **Financial Performance & Debt Profile** The company’s recent financial history reflects significant liquidity challenges and a focus on debt settlement. | Financial Metric | FY 2024-25 | FY 2023-24 | | :--- | :--- | :--- | | **Revenue** | **₹4.45 crore** | *Not explicitly stated* | | **Dividend / Reserve Transfer** | **Nil** | **Nil** | | **Trade Payables (Total)** | **₹95.64 Lakhs** | **₹122.74 Lakhs** | | **Short Term Borrowings** | **Nil** | **₹313.96 Lakhs** | | **Exceptional Gain (OTS)** | — | **₹1.19 crore** | **Credit Status & NPA Management:** * **NPA Classification:** Borrowing accounts were classified as **Non-Performing Assets (NPA)** by various banks and NBFCs as of September 2024. * **One-Time Settlements (OTS):** The company realized an exceptional gain of **₹1.19 crore** in **FY 2023-24** through successful settlements with lenders. * **Security:** Debt is primarily secured by **personal guarantees** and **residential properties** of the promoter directors. --- ### **Operational Efficiency & Growth Drivers** Management is shifting focus toward digital integration and aggressive working capital optimization to improve margins. * **Inventory & Receivables Targets:** * Targeting a reduction in **Inventory Holding Period** from **141 days** (FY25) to **108 days** (FY26). * Aiming to shorten the **Trade Receivable Cycle** from **479 days** to **406 days**. * **B2C Pivot:** Increasing direct-to-consumer presence to mitigate the volatility of B2B hospital contracts, which are prone to vendor changes. * **Resource Optimization:** Growth is currently driven by enhancing **employee multi-tasking** and productivity rather than aggressive headcount expansion. * **Geographic Expansion:** Recent renovation of the **Punjabi Bagh** center targets the West Delhi market and international clientele. * **Procurement Scale:** Leveraging higher sample volumes at the central lab to negotiate better reagent pricing from suppliers like Roche and J&J. --- ### **Critical Risk Factors & Audit Qualifications** Investors should note significant risks related to historical defaults and regulatory compliance. #### **1. Financial & Liquidity Risks** * **Maturity Mismatch:** Heavy reliance on short-term funding and a lack of new working capital limits sanctioned for **FY 2024-25**. * **Uncrystallized Liabilities:** Due to NPA status, the company has not provided for **interest or penal interest** on certain borrowings, potentially understating operational losses. * **Doubtful Debts:** As of September 2025, **₹5.63 crore** in trade receivables remained long-overdue without specific provisioning. #### **2. Audit Qualifications (FY 2024-25)** Statutory auditors have issued qualified opinions regarding: * **Accounting Standard-15:** Non-recognition of **Gratuity** and **Leave Encashment** liabilities. * **Balance Confirmations:** Absence of independent third-party confirmations for receivables, payables, and loans. #### **3. Statutory Non-Compliance** The company has faced "serious delays" in depositing undisputed statutory dues: * **TDS Defaults:** Outstanding balances for **FY 2021-22 through FY 2024-25** (Totaling approx. **₹21.55 lakh**). * **PF & ESI:** Intermittent defaults across **FY 2022-23** and **FY 2023-24**. * **Listing Fees:** History of defaults in paying **Annual Listing Fees (ALF)** to stock exchanges. #### **4. Market & Operational Risks** * **Competitive Pricing:** Intense pressure from **VC-funded startups** offering deep discounts. * **Inventory Obsolescence:** Consumables valued at **₹1.18 crore** are subject to expiry risks. * **Rights Issue Limitations:** A significant portion of the capital raise involves **adjusting existing promoter loans** rather than generating fresh cash inflow for operations.